Research programme: hepatitis C virus NS3/4A protein inhibitors - PhenomixAlternative Names: PHX-B; PHX-C
Latest Information Update: 04 Feb 2011
At a glance
- Originator Phenomix Corporation
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 14 Mar 2007 NS3/4A viral protease inhibitors are available for licensing worldwide (http://www.phenomixcorp.com)
- 13 Mar 2007 Preclinical trials in Hepatitis C treatment in USA (PO)